SCHEMBL3525514

SCHEMBL3525514

CC(C)NS(=O)(=O)c1ccc(F)cc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.54
KDM4E B2RXH2 2/20 0.54
KEAP1 Q14145 1/20 0.44
LPAR2 Q9HBW0 1/20 0.42
ALDH1A1 P00352 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
FABP4 P15090 2/20 0.40
FABP5 Q01469 2/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP3 P08254 1/20 0.40
MMP7 P09237 1/20 0.40
MMP9 P14780 1/20 0.40
MMP13 P45452 1/20 0.40
METAP2 P50579 1/20 0.39
PTGS2 P35354 1/20 0.39
GSTO1 P78417 1/20 0.39
LMNA P02545 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3525941 0.82 NPSR1 (0.54) NPSR1KDM4EALDH1A1GSTO1
SCHEMBL13412195 0.79 POLB (0.50) NPSR1KDM4EALDH1A1LMNA
SCHEMBL3526814 0.78 NPSR1 (0.56) NPSR1KDM4EFABP4FABP5GSTO1
SCHEMBL26212920 0.78 CA1 (0.64) NPSR1KDM4EALDH1A1MMP1MMP2
SCHEMBL3036282 0.77 KEAP1 (0.52) KDM4EKEAP1LPAR2ALDH1A1FABP4
SCHEMBL9321135 0.77 KEAP1 (0.45) KDM4EKEAP1LPAR2ALDH1A1FABP4
SCHEMBL4444797 0.77 KEAP1 (0.55) KDM4EKEAP1LPAR2ALDH1A1FABP4
SCHEMBL3524394 0.75 DPP4 (0.52) NPSR1KEAP1LPAR2
SCHEMBL13544476 0.75 KDM4E (0.52) NPSR1KDM4EALDH1A1GSTO1LMNA
SCHEMBL3531632 0.75 NPSR1 (0.52) NPSR1KDM4EALDH1A1GSTO1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
CN-1744899-A Piperidine derivatives as CCR5 antagonists SMITHKLINE BEECHAM CORP (US) 2006-03-08 CN disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 NPSR1 338/4885KDM4E 4644/4885KEAP1 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.